23例室管膜下巨细胞星形细胞瘤的治疗评价  

Therapeutic review of 23 subependymal giant-cell astrocytoma

作　　者：韩利江[1] 赵继宗[1] 马振宇[1] 林松[1] 赵元立[1] 袁葛[1] 季楠[1] 田永吉[1] 任同[1] 张东[1] 孙振荣[1] 肖新如[1] 唐凯[1] 朴明学[1] 李学记[2] 刘海[1] 叶迅[1] 陈晓霖[1] 

机构地区：[1]首都医科大学附属北京天坛医院神经外科,100050 [2]中国医学科学院肿瘤医院神经外科

出　　处：《中国医师进修杂志（外科版）》2009年第8期18-21,共4页Chinese Journal of Postgraduates of Medicine

摘　　要：目的分析评价室管膜下巨细胞星形细胞瘤（SEGCA）的治疗。方法回顾性研究1995年2月至2008年2月收治的经病理证实的SEGCA23例患者的治疗和预后。结果全切16例，近全切7例，辅助放疗17例。随访1—155个月，平均53个月，肿瘤复发1例，癫痫完全消失占17．6％（3／17），部分改善占47．1％（8／17）。所有病例均存活。结论手术全切是关键，放疗的意义有待确定。SEGCA总体预后较好。Objective To analyze and estimate the treatment of patients with histologically confirmed subependymal giant-cell ＆strocytoma （SEGCA）. Methods The data from 23 patients with SEGCA who were diagnosed between February 1995 and February 2008 were retrospectively evaluated. Various combinations of surgery and radiotherapy had been used for treatment. Results Total resection was 16 cases, subtotal resection was 7 cases, radiotherapy was 17 cases. The average follow-up time was 53 months. One postoperative SEGCA recurrence. Epilepsy was totally disappeared in 17.6% （3/17）, partly disappeared in 47.1% （8/17）. All cases survived. Conclusions The key of treatment is total resection. The significance of radiotherapy is not sure. The overall prognosis of SEGCA is favorable.

关 键 词：室管膜下巨细胞星形细胞瘤 治疗 评估 预后 

分 类 号：R739.41[医药卫生—肿瘤] R329.481[医药卫生—临床医学]